The Lynx Group

Prostate Cancer

Boston, MA—Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer (NEPC), an aggressive and rapidly progressing entity that is increasingly being recognized in patients with advanced disease and signals poor overall survival. The signature, derived from genomic, transcription, and methylation analysis, relies heavily on epigenetic alterations.
Read Article

Enzalutamide (Xtandi) outperformed bicalutamide (Casodex) in separate phase 2 clinical trials of men with prostate cancer, according to data presented at the 2015 American Urological Association annual meeting.
Read Article

New Orleans, LA—Prostate cancer may soon have a new biomarker. The cell surface amino acid glypican-1 (GPC-1) was shown in a pilot study to have specificity of 70% for prostate cancer with a sensitivity of >30%, said Jonathan Henderson, MD, a urologist at Regional Urology in Shreveport, LA, at the 2015 American Urological Association meeting.
Read Article

Orlando, FL—A new retrospective study of 87,562 men diagnosed with prostate cancer between January 2005 and June 2013 show that the incidence of prostate cancer and men with prostate-specific antigen (PSA) >10 decreased gradually between 2005 and 2011. However, the incidence of high-risk prostate cancer at diagnosis increased annually by 3% between 2011 and 2013, totaling 6%. This increase could lead to an additional 1400 prostate cancer deaths 10 years later.
Read Article

Orlando, FL—Experts are hopeful that the field of prostate cancer will soon be catching up to breast cancer and some other tumor types with regard to genomic markers. A study featured at the 2015 Genitourinary Cancers Symposium sug­­gests that the an­drogen receptor (AR) abnormality known as “AR-V7” will turn out to be a predictive marker to help in treatment selection for patients with metastatic castration-resistant prostate can­­cer (CRPC).
Read Article

Chicago, IL—The commercially available cell-cycle progression test known as Prolaris is helpful for stratifying risk for men with clinically localized prostate cancer and can help to modify treatment decisions for men with prostate cancer based on the aggressive nature of their tumor, according to a poster presented at the 2014 College of American Pathologists annual meeting by Michael K. Brawer, MD, Vice President of Medical Affairs, Urology, Myriad Genetic Laboratories, Inc, Salt Lake City, UT, and colleagues.
Read Article

Anew guideline for systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC) is based on a literature review of recent publications and outlines the survival and quality-of-life benefits/toxicity effects of each recommendation (Basch E, et al. J Clin Oncol. 2014 Sept 8. Epub ahead of print).
Read Article

Chicago, IL—The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival (OS) compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study presented at the 2014 American Society of Clinical Oncology meeting.
Read Article

Orlando, FL—Delaying a prostate-specific antigen (PSA)-triggered prostate biopsy to allow for additional PSA assessments might have avoided more than 70% of subsequent biopsies, according to a study of negative biopsies for >28,000 men reported at the 2014 American Urological Association annual meeting.
Read Article

Orlando, FL—Treatment with enzalutamide (Xtandi) after progression with androgen-deprivation therapy (ADT) led to a significant improvement in survival for men with metastatic castration-resistant prostate cancer (mCRPC), according to a new randomized trial reported at the 2014 American Urological Association annual meeting.
Read Article

Page 3 of 6

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: